OVARIAN CANCER and US

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Sunday, May 05, 2013

Case Reports - Necrotizing fasciitis after placement of intraperitoneal catheter



open access

Highlights

Necrotizing fasciitis has not previously been reported in association with placement of intrapertioneal port at the time of cytoreductive surgery
Consensus is lacking regarding the placement of intraperitoneal ports at the time of bowel surgery
Delayed placement of intraperiteonal ports may be considered in patients undergoing bowel resection

Introduction

Intraperitoneal (IP) chemotherapy has a proven survival advantage in patients with optimally cytoreduced advanced epithelial ovarian cancer [1]. Placement of IP catheters can be performed at the time of optimal cytoreductive surgery [2-3]. Reported here is the case of a woman with stage IIIC serous adenocarcinoma of primary peritoneal origin who underwent optimal cytoreductive surgery and IP catheter placement, who was readmitted on post-operative day 10 with necrotizing fasciitis of her anterior abdominal wall originating at the IP catheter site.
Case
A 63-year-old nulligravid female with a past medical history significant for moderately controlled type II diabetes (glycosylated hemoglobin 7.5%), hypertension, hyperlipidemia, and morbid obesity (BMI 44 kg/m2) presented to her primary care physician with complaints of two weeks of lower abdominal pain, bloating, early satiety, and nausea. She was treated with antibiotics for presumed diverticulitis for 2 weeks without resolution of symptoms. A CT scan of the abdomen and pelvis revealed inflammatory changes in the pelvis surrounding the bilateral adnexa and sigmoid colon with multiple colonic diverticula present suggestive of uncomplicated diverticulitis, omental nodularity, and soft tissue prominence in the left adnexa. Pelvic ultrasound showed a 5 cm calcified fibroid with submucosal extension, and the ovaries could not be visualized. A serum CA125 level was elevated to 907 U/mL. She was referred to the Gynecologic Oncology clinic for further evaluation and scheduled for surgery. The patient underwent a diagnostic laparoscopy, which revealed omental caking, moderate straw-colored ascites, and bowel adhesions to the anterior abdominal wall. Due to findings concerning for malignancy, the procedure was converted to laparotomy and optimal cytoreduction to < 1 cm residual disease was performed, including total abdominal hysterectomy, bilateral salpingo-oophorectomy, infragastric omentectomy, appendectomy, resection of proximal descending colon with side-to-side re-anastomosis. IP port was placed at the time of surgery. Surgical pathology showed a stage IIIC high-grade serous adenocarcinoma of primary peritoneal origin.
The immediate post-operative course was uncomplicated and she was discharged home on post-operative day 5. On post-operative day 10, the patient presented to clinic with complaints of increased left sided abdominal pain that she described as a constant, pulling sensation centralized around the IP port site.........

8F-Fluorothymidine PET (PET FLT) Is a Potential Predictive Imaging Biomarker of the Response to Gemcitabine-Based Chemotherapeutic Treatment for Recurrent Ovarian Cancer: Preliminary Results in Three Patients



Abstract

"In order to establish early and precise methods for evaluating the effect of secondary chemotherapy in patients with recurrent ovarian cancer, both the clinical course of 3 women treated with gemcitabine-based secondary chemotherapy and the potential for early and accurate evaluation of the secondary chemotherapeutic effect of F-fluorothymidine (FLT) PET are reported. Standard uptake value with FLT PET decreased earlier than with F-fluorodeoxyglucose PET and was better correlated with a reduction in size as measured by CT. FLT PET could become a new standard for monitoring response to gemcitabine-based secondary chemotherapy treatment for recurrent ovarian cancer."

Isolated Splenic Metastasis of Ovarian Cancer detected with 18F-FDG PET/CT



Abstract

"We report a case of isolated splenic metastasis from ovarian cancer detected with F-FDG PET/CT. A 66-year-old woman with ovarian cancer was referred for F-FDG PET/CT to determine the cause of elevated serum CA-125 levels about 48 months after surgery. F-FDG PET/CT showed focal, intense uptake in the spleen, with no other abnormal findings. A splenectomy was performed, and the lesion was confirmed as metastasis from ovarian cancer pathologically."

CME -- the Oncologist - A study to evaluate the cause of bone demineralization in gynecological cancer survivors



CME

A study to evaluate the cause of bone demineralization in gynecological cancer survivors

About this course


  • Released: April 30, 2013
  • Expires: April 30, 2015
  • Time to Complete: 1.00 hour(s)
  • Medium: Internet Online

Cochrane review:



Abstract including commentaries

BACKGROUND:

This is an updated version of a review that was originally published in the Cochrane Database of Systematic Reviews in 2004, Issue 2. People with cancer, their families and carers have a high prevalence of psychological stress which may be minimised by effective communication and support from their attending healthcare professionals (HCPs). Research suggests communication skills do not reliably improve with experience, therefore, considerable effort is dedicated to courses that may improve communication skills for HCPs involved in cancer care. A variety of communication skills training (CST) courses have been proposed and are in practice. We conducted this review to determine whether CST works and which types of CST, if any, are the most effective.

OBJECTIVES:

To assess whether CST is effective in improving the communication skills of HCPs involved in cancer care, and in improving patient health status and satisfaction.

SELECTION CRITERIA:

The original review was a narrative review that included randomised controlled trials (RCTs) and controlled before-and-after studies. In this updated version, we limited our criteria to RCTs evaluating 'CST' compared with 'no CST' or other CST in HCPs working in cancer care. Primary outcomes were changes in HCP communication skills measured in interactions with real and/or simulated patients with cancer, using objective scales. We excluded studies whose focus was communication skills in encounters related to informed consent for research.

MAIN RESULTS:

We included 15 RCTs (42 records), conducted mainly in outpatient settings. Eleven studies compared CST with no CST intervention, three studies compared the effect of a follow-up CST intervention after initial CST training, and one study compared two types of CST. The types of CST courses evaluated in these trials were diverse. Study participants included oncologists (six studies), residents (one study) other doctors (one study), nurses (six studies) and a mixed team of HCPs (one study). Overall, 1147 HCPs participated (536 doctors, 522 nurses and 80 mixed HCPs).Ten studies contributed data to the meta-analyses. HCPs in the CST group were statistically significantly more likely to use open questions in the post-intervention interviews than the control group (five studies, 679 participant interviews; P = 0.04, I² = 65%) and more likely to show empathy towards patients (six studies, 727 participant interviews; P = 0.004, I² = 0%); we considered this evidence to be of moderate and high quality, respectively. Doctors and nurses did not perform statistically significantly differently for any HCP outcomes.There were no statistically significant differences in the other HCP communication skills except for the subgroup of participant interviews with simulated patients, where the intervention group was significantly less likely to present 'facts only' compared with the control group (four studies, 344 participant interviews; P = 0.01, I² = 70%).There were no significant differences between the groups with regard to outcomes assessing HCP 'burnout', patient satisfaction or patient perception of the HCPs communication skills. Patients in the control group experienced a greater reduction in mean anxiety scores in a meta-analyses of two studies (169 participant interviews; P = 0.02; I² = 8%); we considered this evidence to be of a very low quality.

AUTHORS' CONCLUSIONS:

Various CST courses appear to be effective in improving some types of HCP communication skills related to information gathering and supportive skills. We were unable to determine whether the effects of CST are sustained over time, whether consolidation sessions are necessary, and which types of CST programs are most likely to work. We found no evidence to support a beneficial effect of CST on HCP 'burnout', patients' mental or physical health, and patient satisfaction.


Oncology - Gastrointestinal
Communications training is a mandatory part of our medical oncology trainees' course requirement as a one off workshop during training. This does raise questions as to the utility of this. Prospective assessment is probably required to see if further refreshers are required.
Oncology - General
This Cochrane meta-analysis examines effects of communication skills training on health care practitioners working with patients diagnosed with cancer. Open-ended questions and empathy were significantly increased by training. The duration of these effects and their benefits were unclear. More studies into best practices for communication between cancer care providers and recipients (patients with cancer) are warranted.

Abstracts: meeting conference June 2012 - Annual Meeting of the Italian Society of Uro-Oncology



Blogger's Note: of interest to Lynch Syndrome patients including ovarian cancer patients (rare tumors/uro-oncology/gyn cancer cases....); searchable

ABSTRACTS OF THE 23rd ANNUAL
MEETING OF THE ITALIAN SOCIETY
OF URO-ONCOLOGY (SIUrO)

9-11 June, 2013

book reviews: sundry subjects (for those interested)



(science) book reviews

Genome-wide association study of chemotherapeutic agents-induced severe neutropenia/leucopenia for patients in Biobank Japan



Abstract

Summary

Chemotherapeutic agents are notoriously known to have narrow therapeutic range that often resulted in life-threatening toxicity. Hence, it is clinically important to identify the patients who are at high risk for severe toxicity to certain chemotherapy through a pharmacogenomics approach. In this study, we performed multiple genome-wide association studies (GWASs) of 13,122 cancer patients who received different chemotherapy regimen, including cyclophosphamide-based, platinum-based (cisplatin and carboplatin), anthracycline-based (doxorubicin and epirubicin), antimetabolite-based (5-fluorouracil and gemcitabine), antimicrotubule-agent (paclitaxel and docetaxel), and topoisomerase inhibitor (campthothecin and etoposide) as well as the combination therapy of paclitaxel and carboplatin, to identify genetic variants that are associated with the risk of severe neutropenia/leucopenia in the Japanese population. In addition, we have also carried out a weighted genetic risk scoring (wGRS) system to evaluate the cumulative effects of the suggestive genetic variants identified from GWAS in order to seek a possibility to predict the risk levels of individuals who carry multiple risk alleles. Although we failed to identify genetic variants that surpassed the genome-wide significance level (P<5.0x10-8) through GWASs probably due to insufficient statistical power and complex clinical features, we were able to shortlist some of the suggestive associated loci. The current study is at the relatively preliminary state, but could highlight the complexity and problematic issues in retrospective pharmacogenomics studies. However, we hope that verification of these genetic variants through local and international collaborations could improve the clinical outcome of cancer patients."


Evaluation of Exposures to Healthcare Personnel from Cisplatin during a Mock Demonstration of Intra-operative Intraperitoneal Chemotherapy Administration



Abstract



Highlights

Using personal protection equipment, administration of intraperitoneal cisplatin during optimal debulking surgery is safe to involved healthcare personnel.
This is the first report of its kind to evaluate the safety of healthcare personnel during debulking surgery.

Ovarian cancer is the leading cause of death from gynecologic malignancies in the United States. In 2006, the National Cancer Institute released an announcement supporting the use of intraperitoneal (IP) chemotherapy in advanced ovarian cancer. It remains unanswered how many cycles of IP chemotherapy are required to maintain a survival advantage. There may be a benefit with as few as three IP cycles and possibly as few as one IP chemotherapy cycle.

Objective

In preparation for a clinical trial in which chemotherapy would be administered intra-operatively, the question of exposure to healthcare personnel arose, therefore, the purpose of this study was to perform an evaluation of healthcare personnel exposure to cisplatin during a mock demonstration of intraperitoneal chemotherapy administration.

Materials and Methods

The National Institute of Occupational Safety and Health (NIOSH), the Women’s Cancer Center of Nevada, the staff of the University Medical Center, Las Vegas, participated in this mock demonstration. Employees wore personal protective equipment recommended by NIOSH. Wipe, area, and breathing zone air samples were taken from the pharmacy, operating room, and during sterilization of equipment.

Results

All samples were negative for cisplatin, except for one surface wipe from the floor of the operating room (OR) after the mock procedure. Upon sanitization of the OR, no cisplatin was detected on the floor.

Conclusion

This was the first study evaluating the exposure of healthcare personnel to the administration of cisplatin intra-operatively. NIOSH endorsed this practice so long as the employees adhere to using the recommended personal protective equipment.

U.S. - The Patient Protection and Affordable Care Act: Impact on the care of Gynecologic Oncology patients in the absence of Medicaid expansion(Central Virginia)



Abstract



Highlights
Medicaid expansion opt-out may decrease access to care for low income uninsured and under-insured gynecologic oncology patients in Central Virginia
Minority women and women with cancer will be disproportionately affected

Objective

Many gynecologic oncology (GO) patients in Virginia are low income and their care is supplemented by Disproportionate Share Hospital (DSH) funds. Our objective is to estimate how many new GO patients may lose access to care if the state forgoes Medicaid expansion.

Involved-Field Radiation Therapy for Locoregionally Recurrent Ovarian Cancer (IFRT/note: clear cell)



Blogger's Note: there are no adverse events/effects listed in this abstract; 'definitive' needs to be clarified; requires further information via full research paper to be informative

Involved-Field Radiation Therapy for Locoregionally Recurrent Ovarian Cancer



Highlights

Selected ovarian cancer patients with locoregionally-confined recurrences were treated with definitive involved-field radiation therapy (IFRT).
IFRT produced high rates of in-field disease control and prolonged disease-free intervals of up to 10 years in some patients.
Some patients with disease progression following IFRT may benefit from RT through longer breaks from chemotherapy.

Objective

To evaluate the effectiveness of definitive involved-field radiation therapy (IFRT) for selected patients with locoregionally-recurrent ovarian cancer.

Methods

We retrospectively reviewed records of 102 epithelial ovarian cancer patients treated with definitive IFRT (≥ 45 Gy). IFRT was directed to localized nodal (49%) and extranodal (51%) recurrences.

Results

The median time from diagnosis to IFRT was 36 months (range, 1-311), and the median follow-up after IFRT was 37 months (range, 1-123). Patients received a median of three chemotherapy courses before IFRT (range, 0-9). Five-year overall (OS) and progression-free survival (PFS) rates after IFRT were 40% and 24% respectively; the 5-year in-field disease control rate was 71%.
Thirty-five patients (35%) (??) had no evidence of disease at a median of 38 months after IFRT (range, 7-122), including 25 continuously without disease for a median of 61 months (range, 17-122) and 10 with salvage treatment following disease recurrence, disease-free for a median of 39 months after salvage treatment (range, 7-92).
Eight clear cell carcinoma patients had higher 5-year OS (88% versus 37%; p = 0.05) and PFS (75% versus 20%; p = 0.01) rates than other patients. Patients sensitive to initial platinum chemotherapy had a higher 5-year OS rate than platinum-resistant patients (43% versus 27%, p = 0.03). Patients who required chemotherapy for recurrence after IFRT often benefitted from longer chemotherapy-free intervals after than before IFRT.

Conclusions

Definitive IFRT can yield excellent local control, protracted disease-free intervals, and even cures in carefully selected patients. RT should be considered a tool in the curative management of locoregionally-recurrent ovarian cancer.

Saturday, May 04, 2013

Underutilization of Lynch syndrome screening in a multisite study of patients with colorectal cancer



Abstract

Conclusion: The information required for Lynch syndrome screening decisions is routinely collected but seldom used. There is a critical gap between collection of family history and its use to guide Lynch syndrome screening, which may support a case for implementation of universal screening guidelines.

Clinical Trials | Patient Network (searchable)



Clinical Trials | Patient Network

Clinical Trials

Clinical trials are voluntary research studies conducted in people and designed to answer specific questions about the safety or effectiveness of drugs, vaccines, other therapies, or new ways of using existing treatments. Learn more about clinical trials and find a trial that might be right for you.

Search for a Clinical Trial  

(Blogger's Note: for a quick search, use the text box included below- tested/works fine)

Clear cell adenocarcinoma of the ovary with a sarcoid reaction in the spleen and regional lymph nodes: A case report/review of the literature



open access
  
Highlights
Preoperative diagnosis of sarcoid reactions is important to avoid overtreatments.
Sarcoid reactions could act as a favorable prognostic factor in ovarian cancer.

Introduction

A sarcoid reaction is defined as a phenomenon representing histologically proven granulomatous lesions without evidence of sarcoidosis. Although several reports have been published on sarcoid reactions accompanying malignant tumors (Herxheimer, 1917 and Brincker, 1986), to our knowledge, no study to date has shown an association between sarcoid reactions and epithelial ovarian cancer. In this report, we present a case of clear cell adenocarcinoma of the ovary co-existing with a sarcoid reaction in the lymph nodes and spleen.......

About OVCARE BC'S Ovarian Cancer Research Program



 OVCARE

CMAJ: Mixed reviews on removing fallopian tubes to prevent ovarian cancer (evidence/discussion amongst gyn/onc's)



All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association

CMAJ


Pharmacogenomics explains why some medicines may not work for you



Pharmacogenomics

Experts Tackle Key Issues for Ovarian Cancer in New White Paper | Ovarian Cancer National Alliance



New White Paper - open access



Last fall, the Alliance convened a ground-breaking meeting in Washington, DC, to consider some of the most challenging topics facing the ovarian cancer community. A group of researchers, oncologists, regulatory experts, advocates and industry representatives attempted to answer questions such as: “How can more women be treated where they live?” “How can we facilitate increased awareness and use of patient reported outcomes?” and “What can we expect from personalized medicine in the next few years?”
Our experts’ opinions and recommendations on patient reported outcomes, access to clinical trials at the community level and personalized medicine have been summarized in a white paper and published in an editorial in the journal Gynecologic Oncology.
Download a PDF of our white paper.
Read the editorial in Gynecologic Oncology [subscription required]:

Editorial

Ovarian cancer national alliance: A report of the 2012 Consensus Conference on Current Challenges in ovarian cancer

Purchase $39.95

Don’t play with numbers - Editorial



Editorial - open access
  
This editorial looks at how to present statistical information in a way that is easy for readers to interpret and apply, and calls on everyone involved writing educational material and press releases to make a conscious effort to use the most effective statistical formats.

"Seven simple lifestyle ‘steps’ can cut your risk of getting cancer by 51%. This carefully crafted message, recently publicised by the American Heart Association, was guaranteed to receive enormous media attention because of its simplicity coupled with the promise of halving the risk of contracting a highly feared disease. It is perhaps a good example of linking causes to promote healthier lifestyles. How far it helped anyone understand their own particular risks of getting cancer and how best to manage them, however, is more debatable.

Most of us, when we hear that something halves our risk, tend to think we have understood something meaningful. But if we have little idea about what level of risk we currently face – as is generally the case – then being told that our risk will halve is in practical terms meaningless. Am I halving my risk of ever getting this cancer from 2 in 100,000 to 1 in 100,000? In which case it may make sense to keep the lifestyle and accept the higher risk. Or do I have a 2 in 10 chance of getting that cancer within the next five years, in which case halving that risk to 1 in 10 might be worth some fairly major changes in lifestyle.........  


".........Cancer has always suffered from disinformation and sensationalist claims and scares. The only way to counter this is through consistent and accurate information that is presented in a way that people can easily make sense of. This should become a standard for all educational literature that communicates risks about different aspects of cancer. It should also apply to press releases, so that news about cancer prevention, screening and treatment communicated by the mass media will be genuinely informative and less likely to lead to inaccurate beliefs about the potential of any intervention"

Friday, May 03, 2013

Identification of common variants in BRCA2 and MAP2K4 for susceptibility to sporadic pancreatic cancer (China)



Abstract

Germline mutations in genes that cause hereditary syndromes are highly predisposed to familial pancreatic cancer. However, genetic susceptibility to sporadic pancreatic cancer is largely uncovered. We conducted a two-stage association study on pancreatic cancer that included 981 cases and 1991 controls in the first stage followed by a second stage (2603 cases and 2877 controls). Using an approach based on candidate genes whose roles in pancreatic cancer have been well known, we identified two new susceptibility loci. rs11571836 located in the BRCA2 3′-untranslated region was significantly associated with lower expression of BRCA2 transcript and increased pancreatic cancer risk [odds ratio = 1.30, 95% confidence interval = 1.14–1.47, P = 7.64 × 10–5] in a recessive manner. rs12939944 located in the MAP2K4 intron was associated with decreased risk (odds ratio = 0.82, 95% confidence interval = 0.74–0.91, P = 0.0001) in a dominant manner. Our results demonstrate for the first time that common variants in BRCA2 and MAP2K4 are susceptibility to sporadic pancreatic cancer.

Molecular Genetic Analysis of Bilateral Ovarian Germ Cell Tumors



Abstract

Background:

Ovarian germ cell tumors (oGCTs) are rare and highly heterogeneous with regard to their clinical and histologic appearance. The risk of tumor development is higher in children with aberrant sexual differentiation. Development of gonadoblastomas (large primordial germ cells, immature Sertoli cells or granulosa cells of the sex cord, and gonadal stromal cells) is seen in young women with 46,XY gonadal dysgenesis. At least 50 % of gonadoblastomas may develop into malignant oGCTs, mostly dysgerminomas. In this study, we evaluated bilateral oGCTs in clinically inapparent patients for sex chromosomal aberrations.

Patients and methods:

We analyzed tumor samples of 15 patients with synchronous bilateral oGCTs enrolled onto the consecutive MAKEI trials for non-testicular GCTs.

Fertility and Sterility - Ovarian stimulation in cancer patients



Abstract

Views and reviews


"The patients referred for fertility preservation owing to a malignant disease do not represent the typical population of subfertile patients treated in IVF units. Cancer may affect multiple tissues throughout the body and can result in a variety of complications during controlled ovarian stimulation. Determination of the controlled ovarian stimulation protocol and gonadotropin dose for oocyte/embryo cryopreservation requires an individualized assessment. This review highlights the new protocols that are emerging to reduce time constraints and emphasizes management considerations to decrease complications."

Drug Bank (searchable database)



DrugBank

This project is supported by Genome Alberta & Genome Canada, a not-for-profit organization that is leading Canada's national genomics strategy with $600 million in funding from the federal government. This project is also supported in part by GenomeQuest, Inc., an enterprise genomic information company serving the life science community. 

Non-Steroidal Anti-inflammatory Drugs Decrease E2F1 Expression and Inhibit Cell Growth in Ovarian Cancer Cells (serous)



open access

"Epidemiological studies have shown that the regular use of non-steroidal anti-inflammatory (NSAIDs) drugs is associated with a reduced risk of various cancers. In addition, in vitro and experiments in mouse models have demonstrated that NSAIDs decrease tumor initiation and/or progression of several cancers. However, there are limited preclinical studies investigating the effects of NSAIDs in ovarian cancer. Here, we have studied the effects of two NSAIDs, diclofenac and indomethacin, in ovarian cancer cell lines and in a xenograft mouse model. Diclofenac and indomethacin treatment decreased cell growth by inducing cell cycle arrest and apoptosis. In addition, diclofenac and indomethacin reduced tumor volume in a xenograft model of ovarian cancer. To identify possible molecular pathways mediating the effects of NSAID treatment in ovarian cancer, we performed microarray analysis of ovarian cancer cells treated with indomethacin or diclofenac. Interestingly, several of the genes found downregulated following diclofenac or indomethacin treatment are transcriptional target genes of E2F1. E2F1 was downregulated at the mRNA and protein level upon treatment with diclofenac and indomethacin, and overexpression of E2F1 rescued cells from the growth inhibitory effects of diclofenac and indomethacin. In conclusion, NSAIDs diclofenac and indomethacin exert an anti-proliferative effect in ovarian cancer in vitro and in vivo and the effects of NSAIDs may be mediated, in part, by downregulation of E2F1.........

Retraction notice to "β-Hydroxyisovalerylshikonin has a profound anti- growth activity in human endometrial and ovarian cancer cells"



Retraction notice

Gynecol Oncol. 2013 Apr;129(1):269.

[No authors listed]